Efficacy and Safety of Eletriptan for the Treatment of Migraine in Patients Not Satisfied With Rizatriptan Therapy

Viatris

Status and phase: Completed; Phase 4

Conditions: Migraine

Treatments: Drug: Eletriptan

Study type: Interventional

Funder types: Industry

Identifiers

NCT00632385

A1601092

Details and patient eligibility

About

To assess the efficacy and safety of eletriptan for migraine headaches in subjects who were not satisfied with rizatriptan therapy

Enrollment: 127 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of migraine headache according to International Headache Society criteria and migraine headaches for at least 1 year
• Eletriptan naive
• Previously treated with rizatriptan and failed to achieve a satisfactory response within the past 12 months

Exclusion criteria

• Non-migraine headaches on average more than 6 days per month or have less than 24 hours of freedom from headache between migraine attacks
• Migraine attacks that are atypical or chronic daily headaches
• A history of migraine with prolonged aura, familial hemiplegic migraine, basilar migraine, migrainous infarction, migraine aura without headache, migraine with acute onset aura

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

127 participants in 1 patient group

A

Experimental group

Treatment:

Drug: Eletriptan